Phase 2 N=208 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Advanced BRAF Mutant Cancers
Primary: Dose-limiting Toxicities (DLTs) — 0 DLTs
Phase 2 N=206 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Phase 2 N=4 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Phase 2 N=9 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
Phase 2 N=28 Selumetinib in Cancers With BRAF Mutations
Adult Solid Neoplasm
Primary: Objective Response Rate in Patients With Cancers Other Than Melanoma — 0 percentage of participants
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Phase 2 N=49 Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
N/A N=274 A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
BRAF V600E Mutation Positive · Metastatic Colorectal Cancer
Primary: Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients — 17; 6; 10; 1 Participants
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
Phase 2 N=177 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Phase 2 N=7 BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
Phase 2 N=172 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 2 N=95 Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments — 47.8 percentage of confirmed responses
Phase 2 N=158 LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Melanoma
Primary: Overall Response Rate (ORR): Part II — 2.6; 0; 0; 0 Percentage of participants
Phase 2 N=92 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Phase 2 N=98 An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) — 74.6; 46.2 Percentage of Participants
Phase 3 N=921 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Melanoma
Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months
Phase 1 N=8 Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Thyroid Carcinoma · Thyroid Cancer · Thyroid Cancer, Follicular
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
N/A N=662 A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Multiple Myeloma, Neoplasms
Primary: Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type — 0; 3; 11; 0 percentage of participants
N/A N=716 Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Melanoma
Primary: Overall Survival (OS) — 16.1; 25.0; 30.0 Months — p=0.02
Phase 1 N=54 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants
Phase 2 N=106 S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival — 2.0; 4.3 months — p=0.001
Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months